89bio - ETNB Total Company Value-to-Revenue Ratio

Corporate company logo of 89bio.com (ETNB)

The resilience of 89bio, Inc. (ETNB) is limited by a high success rate dependency on a single drug, which is confirmed by the EV/Sales trend, where the metric stands at . The company's revenues will be based on the commercialization of NASH therapy. Business development relies on FDA approval and the inflow of investments, as the company is currently in the clinical trial stage.

ETNB 89bio, Inc.: Enterprise Value-to-Revenue Ratio in the range 07/04/2022 - 11/20/2026

89bio Corp - analytical breakdowns and key metrics (ETNB)

- share price and expert price forecast:
Fundamental company valuation:ETNB (89bio.com)
Original product of 89bio Inc

Analyzing business value net of debt relative to operating income is critical for selecting assets with a high margin of safety. This metric measures capital structure efficiency, which for 89bio, Inc. (ETNB) allows for an assessment of pegozafermin's market potential and the likelihood of acquisition by pharma behemoths by tracking valuation trends via the EV/Sales ratio.

Competitor analysis

ASND: Enterprise Value-to-Revenue Ratio|MDGL: EV/Sales Multiple|CORT - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Rhythm Corp|Akero Corp (AKRO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio metsera.com (MTSR)|Company Value to Revenue moonlaketx.com MLTX|EV/Sales Multiple CRNX (Crinetics Pharmaceuticals, Inc.)|NAMS: Company Value to Revenue Ratio|SLNO - Enterprise Value-to-Revenue Ratio|Amicus Pharma (FOLD) - Company Value to Revenue|AGIO: EV/Sales Multiple|Structure Therapeutics Inc. - Business Value to Revenue|MDXG (MiMedx Corp) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Rezolute Inc RZLT|EV/Sales Multiple LXRX|Total Company Value-to-Revenue Ratio MBX Corp|Altimmune Pharma - Company Value to Revenue|EV/Sales Multiple aardvarktherapeutics.com AARD|SGMT: Company Value to Revenue|Business Value to Revenue BIOA (BioAge Labs)|BMEA: EV/Sales Multiple|QNCX: Enterprise Value-to-Revenue Coefficient|GUTS (Fractyl Health, Inc.) - EV/Sales Multiple|EV/Sales Multiple vtvtherapeutics.com|Company Value to Revenue ATPC (Agape ATP Corp)|Total Company Value-to-Revenue Ratio Pluristem Therapeutics|Enterprise Value-to-Revenue Ratio synlogictx.com SYBX|LPCN: Company Value to Revenue Ratio|MTNB - Enterprise Value-to-Revenue Ratio|Spruce Biosciences, Inc. (SPRB) - Company Value to Revenue|GLTO: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - EV/Sales Multiple|Organovo Corp (ONVO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Radius Recycling (RDUS)